Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19
Autor: | Prabhakaran, Dorairaj, Singh, Kavita, Kondal, Dimple, Raspail, Lana, Mohan, Bishav, Kato, Toru, Sarrafzadegan, Nizal, Talukder, Shamim Hayder, Akter, Shahin, Amin, Mohammad Robed, Goma, Fastone, Gomez-Mesa, Juan, Ntusi, Ntobeko, Inofomoh, Francisca, Deora, Surender, Philippov, Evgenii, Svarovskaya, Alla, Konradi, Alexandra, Puentes, Aurelio, Ogah, Okechukwu S., Stanetic, Bojan, Issa, Aurora, Thienemann, Friedrich, Juzar, Dafsah, Zaidel, Ezequiel, Sheikh, Sana, Ojji, Dike, Lam, Carolyn S.P., Ge, Junbo, Banerjee, Amitava, Newby, L. Kristin, Ribeiro, Antonio Luiz P., Gidding, Samuel, Pinto, Fausto, Perel, Pablo, Sliwa, Karen, WHF COVID-19 Study Collaborators, On Behalf of the |
---|---|
Přispěvatelé: | Repositório da Universidade de Lisboa, Cardiovascular Centre (CVC) |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Heart Failure
Male Community and Home Care Epidemiology MORTALITY Aftercare COVID-19 Middle Aged Patient Discharge mortality cardiovascular disease Hospitalization TRIALS Cardiovascular Diseases Heart Disease Risk Factors Risk Factors RELATIVE RISK Diabetes Mellitus Humans COHORT Prospective Studies Cardiology and Cardiovascular Medicine INFLUENZA VACCINATION |
Zdroj: | Global Heart; Vol 17, No 1 (2022); 40 Global heart, 17(1):40. ELSEVIER SCIENCE INC |
ISSN: | 2211-8160 2211-8179 |
DOI: | 10.5334/gh.1128 |
Popis: | © 2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/ licenses/by/4.0/. Background and aims: Limited data exist on the cardiovascular manifestations and risk factors in people hospitalized with COVID-19 from low- and middle-income countries. This study aims to describe cardiovascular risk factors, clinical manifestations, and outcomes among patients hospitalized with COVID-19 in low, lower-middle, uppermiddle- and high-income countries (LIC, LMIC, UMIC, HIC). Methods: Through a prospective cohort study, data on demographics and pre-existing conditions at hospital admission, clinical outcomes at hospital discharge (death, major adverse cardiovascular events (MACE), renal failure, neurological events, and pulmonary outcomes), 30-day vital status, and re-hospitalization were collected. Descriptive analyses and multivariable log-binomial regression models, adjusted for age, sex, ethnicity/income groups, and clinical characteristics, were performed. Results: Forty hospitals from 23 countries recruited 5,313 patients with COVID-19 (LIC = 7.1%, LMIC = 47.5%, UMIC = 19.6%, HIC = 25.7%). Mean age was 57.0 (±16.1) years, male 59.4%, pre-existing conditions included: hypertension 47.3%, diabetes 32.0%, coronary heart disease 10.9%, and heart failure 5.5%. The most frequently reported cardiovascular discharge diagnoses were cardiac arrest (5.5%), acute heart failure (3.8%), and myocardial infarction (1.6%). The rate of in-hospital deaths was 12.9% (N = 683), and post-discharge 30 days deaths was 2.6% (N = 118) (overall death rate 15.1%). The most common causes of death were respiratory failure (39.3%) and sudden cardiac death (20.0%). The predictors of overall mortality included older age (≥60 years), male sex, pre-existing coronary heart disease, renal disease, diabetes, ICU admission, oxygen therapy, and higher respiratory rates (p < 0.001 for each). Compared to Caucasians, Asians, Blacks, and Hispanics had almost 2–4 times higher risk of death. Further, patients from LIC, LMIC, UMIC versus. HIC had 2–3 times increased risk of death. Conclusions: The LIC, LMIC, and UMIC’s have sparse data on COVID-19. We provide robust evidence on COVID-19 outcomes in these countries. This study can help guide future health care planning for the pandemic globally. Dr. Kavita Singh is supported by the National Institutes of Health, Fogarty International Centre, USA; Emerging Global Leader grant award number: 1 K43 TW011164. Dr Antonio Luiz P. Ribeiro is supported in part by Brazilian Agencies CNPq (310679/2016-8 and 465518/2014-1), by FAPEMIG (PPM-00428-17) and CAPES (88887.507149/2020-00). Dr Karen Sliwa acknowledges support from the Hippocrate Foundation and the Medical Research Council South Africa. Friedrich Thienemann is supported by European and Developing Countries Clinical Trials Partnership (EDCTP) of the European Union. |
Databáze: | OpenAIRE |
Externí odkaz: |